Previous close | 2.0000 |
Open | 2.0000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 4.00 |
Expiry date | 2026-01-16 |
Day's range | 2.0000 - 2.0000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Shares of Geron (GERN) are trading higher Friday, propelled by the recent Food & Drug Administration (FDA) approval of the company's blood disorder drug, Rytelo. The treatment is for adults with low- to intermediate-1 risk of myelodysplastic syndromes, a type of cancer. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.